It has been suggested that other cancer types may become ‘addicted’ to Bcl3 and that a loss of Bcl3 can specifically disrupt tumour cell survival, further adding to the appeal of targeting Bcl3 therapeutically [33,34]. The gene discussed is BCL3; the disease is cancer.